Clinical Trial Update: An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis [Phase 2]

View source ↗

Summary

Phase II safety study and open-label demonstration of pre-exposure prophylaxis (PrEP) for HIV infection; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: HIV Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-12-21